The topics this week range from superficial to visceral, and from head to spleen. See if you can answer all 5 questions.
QUESTION 1:
For the discussion, click here.
Click here for the next question.
For the answers, click here.
QUESTION 2:
For the discussion, click here.
Click here for the next question.
For the answers, click here.
QUESTION 3:
For the discussion, click here.
Click here for the next question.
For the answers, click here.
A 53-year-old woman presented with sudden onset of left upper quadrant abdominal pain. Abdominal examination revealed a soft, nontender abdomen with normal bowel sounds and no hepatosplenomegaly.
QUESTION 4:
For the discussion, click here.
Click here for the next question.
For the answers, click here.
QUESTION 5:
For the discussion, click here.
For the answers, click here.
ANSWER KEY:
Question 1. Answer: g
Question 2. Answer: b
Question 3. Answer: a
Question 4. Answer: a
Question 5. Answer: b
Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD
June 11th 2025RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.